BEAM-302
BTX-302-001
Phase 2 small_molecule active
Quick answer
BEAM-302 for Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease and/or Liver Disease is a Phase 2 program (small_molecule) at Beam Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Beam Therapeutics
- Indication
- Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease and/or Liver Disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active